Navigation Links
The ideal composition of intravenous lipid emulsion

The body responds to a diverse range of insults, such as surgery, infection and injury by the activation of a wide range of cell types of the immune system, creating a number of potent cellular actions and mediators.// The inflammatory response, although essential for fighting infection, may damage the host. Its strength depends on pro- and anti-inflammatory mediators, cytokines and lipid mediators being the key mediators.

Recently, Robert Grimble, from the Institute of Human Nutrition, School of Medicine, University of Southampton, UK has reviewed the fatty acid profile of modern lipid emulsions, and the scientific considerations for creating the ideal composition.

In his report published in volume 1 of Clinical Nutrition Supplements, he states that in some types of patients, the lack of a correctly functioning gut precludes complete oral or enteral nutrient provision. As a consequence, the intravenous route assumes a greater importance for the provision of energy substrates, amino acids and micronutrients. Reliance on glucose as the main provider of energy to patients requiring intravenous nutrition led to metabolic complications. These include insulin insensitivity and metabolic acidosis due to the need to dispose of a large amount of metabolic breakdown products in the form of carbon dioxide.

Intravenous nutrition has been a life-saving technique in the treatment of severely ill patients, particularly in those where normal gut function is absent. However, the inability to provide sufficient energy to patients, in the form of glucose, led to the development of intravenous lipid emulsions.

These products were a major breakthrough in clinical nutrition particularly as insulin insensitivity is a major feature in the metabolism of severely ill patients. Previous studies have indicated that the use of lipid emulsions in clinical nutrition is not without limitations, but the inclusion of ù-3 fatty acids and fats rich in MUFAs a nd anti-oxidants in intravenous nutrition may successfully modulate inflammation and immunosuppression.

The creation of soybean oil-based lipid emulsions, for use in parenteral nutrition, was an important landmark in the science of nutritional treatment of surgical patients and individuals requiring critical care.

The primary importance of this development was that the energy requirements of the patient could be met without the metabolic burden imposed by high-level glucose infusion in situations of respiratory distress and insulin insensitivity. In soybean oil-based emulsions the ratio of ù-6 to ù-3 fatty acids is approximately 7:1. These classes of fatty acids compete for inclusion in cell membranes and result in the production of lipid mediators of differing potency.

The authors concludes on the note that recent studies suggest that increasing the ratio of ù-3 to ù-6 fatty acids and raising the monounsaturated fatty acid (MUFA) content of intravenous lipid emulsion is beneficial. MUFAs exert a neutral effect on metabolism. Thus ideal lipid solutions can be designed by adjustment of the ratio of ù-3, ù-6 and MUFAs
'"/>




Related medicine news :

1. The Link Between Oxidized Phospholipids And Coronary Artery Disease
2. Patients with HIV-1 can predict plasma lipids level based on race
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... CO (PRWEB) , ... December 02, 2016 , ... Advanced ... announced it has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief ... for Advanced, Inc. , Jason brings extensive financial and operational leadership experience to ...
(Date:12/2/2016)... Raleigh, NC (PRWEB) , ... December 02, 2016 , ... ... the Open Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare ... plan (Part C) or prescription drug plan (Part D) need to make changes during ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet’s newest campaign, “Digestive Heath,” hits ... proof that attitude and determination can combine into the most remarkable achievements. Over ... holidays. This campaign will offer patients a new-found hope, by seizing the opportunity ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is ... USA Today, which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that ... “We are prolonging life 6 years in the last 3 decades,” says Dr. ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... veterinarian diagnostic imaging systems and the first company to offer robotic imaging ... Heart at their tradeshow booth # 941 for the American Association of Equine ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Dec. 2, 2016 Lianluo Smart Limited ... "the Company") which develops, markets and sells medical ... China and international markets, recently ... and Treatment New Progress Forum, co-hosted by the ... Province , Guangdong Provincial People,s Hospital and ...
(Date:12/2/2016)... Dec. 1, 2016 The concept of rare diseases ... given to this sector has been taking shape in ... the political aspects and initiatives related to orphan medicinal products ... the level of member states individually. Many member states in ... the space of orphan medicinal products, the result of which ...
(Date:12/2/2016)... Allergan plc (NYSE: AGN ), a ... previously announced Accelerated Share Repurchase (ASR) Program. Logo - ... ... previously announced, the Company entered into a variable tenor ASR ... repurchase $10 billion of its ordinary shares. Approximately 40.5 million ...
Breaking Medicine Technology: